Here are the DEF 14A proxy statements from Galectin Therapeutics Inc. (GALT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow GALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GALT filings page.
Galectin Therapeutics Inc. (GALT) is asking stockholders to elect 11 directors and vote on three other proposals at its virtual annual meeting on December 3, 2026: increasing authorized common stock from 150,000,000 to 250,000,000 shares, reserving an additional 3,000,000 shares under its 2019 Omnibus Equity Incentive Plan, and ratifying Cherry Bekaert LLP as auditor for 2026. Common and Series A preferred holders of record on October 6, 2026 may vote.
On July 31, 2026, Richard E. Uihlein, the company’s chairman and largest stockholder, converted all outstanding convertible notes from prior credit facilities. The conversion eliminated $91.0 million in principal and approximately $14.8 million in accrued interest—approximately $105.8 million total—in exchange for 34,376,167 common shares at a blended average conversion price of approximately $3.07 per share. The shares remain subject to resale restrictions; Galectin must file a resale registration statement within 180 days after Uihlein’s written request and use commercially reasonable efforts to make it effective as promptly as practicable thereafter.